308 related articles for article (PubMed ID: 20215530)
1. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
[TBL] [Abstract][Full Text] [Related]
2. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Naumovski L; Junutula JR
Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
[TBL] [Abstract][Full Text] [Related]
3. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
[TBL] [Abstract][Full Text] [Related]
4. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
[TBL] [Abstract][Full Text] [Related]
5. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
[TBL] [Abstract][Full Text] [Related]
7. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
[TBL] [Abstract][Full Text] [Related]
8. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
9. GPNMB expression in uveal melanoma: a potential for targeted therapy.
Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
[TBL] [Abstract][Full Text] [Related]
10. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
[TBL] [Abstract][Full Text] [Related]
11. Osteoactivin promotes breast cancer metastasis to bone.
Rose AA; Pepin F; Russo C; Abou Khalil JE; Hallett M; Siegel PM
Mol Cancer Res; 2007 Oct; 5(10):1001-14. PubMed ID: 17951401
[TBL] [Abstract][Full Text] [Related]
12. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
Mehta K; Fok J; Miller FR; Koul D; Sahin AA
Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
[TBL] [Abstract][Full Text] [Related]
14. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
[TBL] [Abstract][Full Text] [Related]
15. DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer.
Germain DR; Graham K; Glubrecht DD; Hugh JC; Mackey JR; Godbout R
Breast Cancer Res Treat; 2011 May; 127(1):53-63. PubMed ID: 20499159
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
17. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients.
de Kruijf EM; van Nes JG; van de Velde CJ; Putter H; Smit VT; Liefers GJ; Kuppen PJ; Tollenaar RA; Mesker WE
Breast Cancer Res Treat; 2011 Feb; 125(3):687-96. PubMed ID: 20361254
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
19. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
20. Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients.
Dales JP; Garcia S; Bonnier P; Duffaud F; Meunier-Carpentier S; Andrac-Meyer L; Lavaut MN; Allasia C; Charpin C
Int J Oncol; 2003 Feb; 22(2):391-7. PubMed ID: 12527939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
